Items Tagged ‘CDK4/6 inhibitor’

February 13, 2018

Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer


CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. Results from […]

View full entry

Tags: Breast Cancer, CDK4/6 inhibitor, kisqali, News, ribociclib, treatment